Immunogen (IMGN) Misses Q1 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Immunogen (IMGN) Misses Q1 EPS by 4c

ImmunoGen Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update

October 27, 2015 6:30 AM EDT

Conference Call Today at 8:00 am ET

Level of target expression on patient tumors may have a marked impact on response to mirvetuximab soravtansine, ImmunoGens novel folate receptor (FR)-targeting antibody-drug conjugate (ADC); data to be reported at AACR-NCI-EORTC in November. Patient enrollment completed in Phase 1 ovarian cancer cohort that ImmunoGen plans to discuss with regulators in 2016. Company on track to initiate trials designed to potentially support an Accelerated Approval pathway (FORWARD I) and market expansion (FORWARD II) for mirvetuximab soravtansine. Broader pipeline progress includes advancement of another... More